You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Aspiro Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ASPIRO

ASPIRO has twenty-one approved drugs.



Summary for Aspiro
US Patents:0
Tradenames:19
Ingredients:19
NDAs:21

Drugs and US Patents for Aspiro

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aspiro SUGAMMADEX SODIUM sugammadex sodium SOLUTION;INTRAVENOUS 214337-001 Jun 9, 2023 AP RX No No ⤷  Try for Free ⤷  Try for Free
Aspiro KETOROLAC TROMETHAMINE ketorolac tromethamine INJECTABLE;INJECTION 217166-002 Jun 20, 2023 AP RX No No ⤷  Try for Free ⤷  Try for Free
Aspiro LACOSAMIDE lacosamide SOLUTION;INTRAVENOUS 216335-001 Sep 14, 2022 AP RX No No ⤷  Try for Free ⤷  Try for Free
Aspiro FUROSEMIDE furosemide INJECTABLE;INJECTION 217557-001 Dec 13, 2024 AP RX No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Aspiro – Market Position, Strengths & Strategic Insights

In the dynamic and highly competitive pharmaceutical industry, understanding the market landscape is crucial for success. This article delves into a comprehensive analysis of Aspiro, examining its market position, strengths, and strategic insights that shape its competitive edge.

Aspiro: An Overview

Aspiro Pharma Ltd., established in 2014, has rapidly emerged as a significant player in the Indian pharmaceutical sector. The company specializes in the research, development, and manufacturing of Generic Parenteral Formulations, with a particular focus on injectables[1][8].

Core Competencies

Aspiro's core competencies lie in manufacturing powder, lyophilized, and liquid products as injectables, ophthalmic solutions, pre-filled syringes (PFS), and IV Bags. These products find applications across a wide range of therapeutic areas, including cardiovascular, central nervous system (CNS), ophthalmology, anesthetics, anti-ulcerative treatments, and more[7].

Market Position and Growth Trajectory

Aspiro has positioned itself as a fast-growing pharmaceutical company in India, with a clear focus on parenteral formulations. The company's growth trajectory is evident from its expanding product portfolio and increasing revenue[5].

Revenue Growth

Aspiro's total operating revenue increased from ₹90.11 crore in FY22 to ₹103.24 crore in FY23, demonstrating a positive growth trend. In the first half of FY24, the company reported revenue of ₹94.29 crore, indicating potential for further growth[7].

Product Portfolio Expansion

The company has been steadily expanding its product portfolio, which now spans multiple therapeutic segments. As of recent reports, Aspiro has a portfolio of around 26 products, with ANDA approvals for 13 and several more in the pipeline[7].

Manufacturing Capabilities and Infrastructure

One of Aspiro's key strengths lies in its state-of-the-art manufacturing facilities, which play a crucial role in its market positioning.

Advanced Manufacturing Facility

Nestled in an expanse of 10 acres and located close to city of Hyderabad, Aspiro Pharma has state-of-the-art manufacturing facilities with design standards conforming to Schedule M of Indian Drugs & Cosmetics Act, USFDA and European Regulatory Agency's Guidelines.[10]

Production Capacity

Aspiro's manufacturing facility boasts impressive production capabilities:

  • Two existing production lines with capacities of 65 lakh and 1.3 crore injections
  • Two new production lines, each with a capacity of around 3 crore injections
  • All production facilities are USFDA approved[7]

Quality Certifications

The company's commitment to quality is evident from its numerous certifications:

  • GMP certified by Ukraine Medical and Drug Control
  • ANVISA Brazil certification
  • UAE Ministry of Health certification
  • INVIMA Colombia certification[7]

Research and Development Focus

Aspiro's dedication to innovation is reflected in its R&D efforts, which form a cornerstone of its competitive strategy.

R&D Recognition

Aspiro's in-house R&D unit has been recognized by the Department of Scientific and Industrial Research (DSIR), underscoring the company's commitment to advancing pharmaceutical research[1].

Product Development Pipeline

The company is actively engaged in developing new products, with plans to introduce 5-6 new offerings based on market demand. This ongoing R&D effort is expected to further diversify and strengthen Aspiro's product portfolio[7].

Market Reach and Export Focus

Aspiro has established a strong presence in international markets, particularly in the United States.

Export-Oriented Business Model

A significant portion of Aspiro's revenue, ranging from 75-80% in FY23 and H1FY24, is derived from exports to the US market. This export-oriented approach demonstrates the company's global ambitions and its ability to meet international quality standards[7].

Competitive Strengths

Several factors contribute to Aspiro's competitive edge in the pharmaceutical landscape:

1. Specialized Focus

Aspiro's specialization in injectable formulations allows it to concentrate its resources and expertise in a niche but critical area of pharmaceutical manufacturing.

2. Quality Assurance

The company's adherence to international quality standards and multiple certifications enhances its credibility and market access.

3. Research-Driven Approach

Aspiro's recognized R&D unit and ongoing product development efforts position it well for future growth and innovation.

4. Strategic Location

The company's manufacturing facility, located near Hyderabad, provides strategic advantages in terms of logistics and access to skilled workforce.

Challenges and Areas for Improvement

While Aspiro has demonstrated significant strengths, it also faces certain challenges that require strategic attention:

1. Product Concentration

Despite a growing portfolio, Aspiro's revenue is still heavily dependent on a few key products. In FY23 and H1FY24, the top 5 products contributed to about 70% of the total revenue[7].

2. Geographical Concentration

The company's high reliance on the US market for exports (75-80% of revenue) exposes it to potential risks associated with market-specific fluctuations or regulatory changes[7].

3. Financial Performance

Aspiro has reported operating losses in recent years, which is attributed to the initial years of operations for injectables and limited scale of operations. However, this is expected to improve with growing scale and new product approvals[7].

Strategic Insights and Future Outlook

Based on the analysis of Aspiro's current position and market trends, several strategic insights emerge:

1. Diversification Opportunities

Aspiro could benefit from diversifying both its product portfolio and geographical reach to mitigate concentration risks.

2. Scale Optimization

Focusing on optimizing production scale and efficiency could help improve financial performance and profitability.

3. Innovation Focus

Continued investment in R&D and new product development will be crucial for maintaining competitiveness and driving growth.

4. Market Expansion

Exploring new international markets beyond the US could provide additional growth avenues and reduce geographical concentration.

5. Strategic Partnerships

Collaborations or partnerships with other pharmaceutical companies or research institutions could enhance Aspiro's capabilities and market reach.

Industry Trends and Aspiro's Positioning

The pharmaceutical industry is experiencing several key trends that Aspiro must navigate:

1. Increased Focus on Innovation

The industry is seeing a shift towards more innovative and specialized treatments. Aspiro's strong R&D focus positions it well to capitalize on this trend.

2. Growing Demand for Injectables

The global market for injectable drugs is expanding, aligning well with Aspiro's core competencies.

3. Regulatory Challenges

Increasing regulatory scrutiny in the pharmaceutical industry underscores the importance of Aspiro's quality certifications and compliance efforts.

4. Shift Towards Patient-Centric Models

As the industry moves towards more patient-centric approaches, Aspiro may need to adapt its strategies to align with this trend.

Competitive Intelligence Strategies for Aspiro

To maintain and enhance its competitive position, Aspiro could consider implementing the following competitive intelligence strategies:

1. Systematic Competitor Analysis

Regularly analyzing competitors' product portfolios, R&D pipelines, and market strategies can provide valuable insights for strategic decision-making.

2. Patent Landscape Monitoring

Keeping a close eye on patent filings and expirations in relevant therapeutic areas can help identify potential opportunities and threats.

3. Clinical Trial Tracking

Monitoring ongoing clinical trials in injectable formulations can provide early insights into emerging treatments and potential market shifts.

4. Regulatory Environment Scanning

Staying abreast of regulatory changes and trends, particularly in key markets like the US, is crucial for maintaining compliance and identifying new opportunities.

5. Customer Feedback Analysis

Gathering and analyzing feedback from healthcare providers and patients can inform product development and improvement efforts.

Key Takeaways

  • Aspiro Pharma has established itself as a fast-growing player in the Indian pharmaceutical industry, specializing in injectable formulations.
  • The company's strengths lie in its state-of-the-art manufacturing facilities, strong R&D focus, and quality certifications.
  • Aspiro faces challenges related to product and geographical concentration, as well as financial performance in its early growth stages.
  • Strategic opportunities include diversification, scale optimization, continued innovation, and market expansion.
  • Implementing robust competitive intelligence strategies will be crucial for Aspiro to maintain and enhance its market position.

FAQs

  1. What is Aspiro Pharma's primary focus in the pharmaceutical industry? Aspiro Pharma specializes in the research, development, and manufacturing of Generic Parenteral Formulations, with a particular emphasis on injectable products.

  2. How has Aspiro's revenue growth been in recent years? Aspiro's total operating revenue increased from ₹90.11 crore in FY22 to ₹103.24 crore in FY23, with ₹94.29 crore reported in the first half of FY24, indicating a positive growth trend.

  3. What are some of the key challenges facing Aspiro Pharma? Key challenges include product and geographical concentration, with a high reliance on a few products and the US market, as well as financial performance issues in the early stages of growth.

  4. How is Aspiro positioned in terms of research and development? Aspiro has a strong R&D focus, with its in-house R&D unit recognized by the Department of Scientific and Industrial Research (DSIR), and ongoing efforts to develop new products based on market demand.

  5. What competitive intelligence strategies could benefit Aspiro? Systematic competitor analysis, patent landscape monitoring, clinical trial tracking, regulatory environment scanning, and customer feedback analysis are key competitive intelligence strategies that could benefit Aspiro.

Sources cited:

  1. https://www.aspiropharma.com
  2. https://economictimes.indiatimes.com/company/aspiro-pharma-limited/U24100TG2014PLC092771
  3. https://www.careratings.com/upload/CompanyFiles/PR/202402140219_Aspiro_Pharma_Limited.pdf
  4. https://www.greatplacetowork.in/great/company/aspiro-pharma-ltd
  5. https://www.aspiropharma.com/manufacturing.php

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.